Madison Clarke
The US Centers for Disease Control and Prevention (CDC) does hold patents, including patents for drugs and vaccines. The CDC licenses technology developed at the CDC to third parties, and companies can license this technology and pay royalties to the CDC and inventors. The CDC's Technology Transfer Office explains that this dissemination advances the CDC's public health mandate. While the CDC does own and license some patents related to vaccines and vaccine technologies, they don't sell vaccines. Instead, they buy vaccines at a discount and provide them for free to children who can't afford them.
| Characteristics | Values |
|---|---|
| Does the CDC hold vaccine patents? | Yes, the CDC does hold vaccine patents and licenses some patents related to vaccine technologies. |
| Does the CDC sell vaccines? | No, the CDC does not sell vaccines. It buys them at a discount and distributes them for free, especially to children who can't afford them. |
| Does the CDC hold drug patents? | The CDC holds patents on the EboBun strain of Ebola and a nasal drug delivery apparatus. |
Explore related products
What You'll Learn
- The CDC holds patents for technologies used in vaccine development and manufacturing
- The CDC licenses these technologies to third parties, receiving royalties
- The CDC does not sell vaccines but distributes them for free
- The CDC holds a patent for the EboBun strain of Ebola
- The CDC also holds patents for other technologies, such as nasal drug delivery
The CDC holds patents for technologies used in vaccine development and manufacturing
The US Centers for Disease Control and Prevention (CDC) holds patents for technologies used in vaccine development and manufacturing. The CDC is a federal agency and not a vaccine company. It does not sell vaccines but instead buys them at a discount and distributes them for free, particularly to children who cannot afford them. The CDC's Technology Transfer Office explains that researchers at the CDC may develop new technologies that could be of interest to companies. To advance the CDC's public health mandate, these technologies are made available to the private sector through licenses. Companies can then use these technologies to develop or manufacture products such as vaccines. The CDC received $17 million in royalties from patented and unpatented technologies in 2019.
The CDC holds patents for technologies related to the Zika virus, anthrax, influenza A, and Ebola. The CDC's patent on the EboBun strain of Ebola, for example, allows researchers to work with the strain without fees and prevents commercial companies from patenting it for profit. The CDC also holds patents on vaccine compositions, such as a composition comprising a VDV1 strain for a dengue vaccine.
It is important to note that the CDC's ownership of patents does not mean that it is profiting from vaccine sales. The CDC's goal in holding patents is to support its mission of protecting public health and ensuring that innovations benefit the health of Americans and people worldwide.
Arrowhead Stadium's COVID-19 Vaccination Policy Explained
You may want to see also
Explore related products
The CDC licenses these technologies to third parties, receiving royalties
The CDC does hold patents, including those for technologies used in the process of developing or manufacturing vaccines. However, it is important to note that the CDC does not sell vaccines. Instead, it buys vaccines in bulk at discounted prices and distributes them for free to children from low-income families through the Vaccines for Children (VFC) program and Section 317 grants.
The CDC's patents cover a range of vaccine and drug delivery technologies. For example, the CDC holds a patent on a recombinant antigen derived from the Zika virus E protein, which can be used to develop a DNA vaccine composition. They also have a patent for a method of increasing the recombinant expression and solubility of influenza A virus M2 polypeptide, which can be used for vaccines and diagnostics. Additionally, the CDC holds a patent on an apparatus for nasal drug delivery, which involves using negative pressure to deposit an aerosol on the internal nasal surface.
While the CDC does license its technologies and receive royalties, it is important to clarify that the CDC is not a for-profit vaccine company. The royalties received are used to fund further public health initiatives and technology development. The CDC's primary role is to protect public health and support communities, rather than generating profits from vaccine sales.
Vaccine Approval: FDA's Role and Importance
You may want to see also
Explore related products
The CDC does not sell vaccines but distributes them for free
The CDC is a federal agency and not a vaccine company. It holds patents, many of which cover technology used in the process of developing or manufacturing vaccines. Companies can license this technology and pay royalties to the CDC and inventors. However, this does not mean that the CDC sells vaccines. The royalties received are reinvested into developing additional technologies that meet public health needs.
The CDC's Technology Transfer Office explains that the goal of holding patents is to "support CDC's mission by facilitating the development and transition of CDC innovations into products that benefit the health of Americans and people around the world." The CDC researchers may develop new technologies that could be of interest to companies, and these technologies are disseminated to others to advance the CDC's public health mandate.
The CDC received $17 million in total royalties from patented and unpatented technologies in 2019. Its budget for the vaccine distribution program in the same year was $4.6 billion, which is the amount spent by the CDC to provide vaccines and not the amount gained from vaccine sales.
While the CDC does own and license some patents related to vaccines and vaccine technologies, it is important to note that the CDC does not sell vaccines.
Vaccines: Do They Stay in Our Bodies?
You may want to see also
Explore related products
The CDC holds a patent for the EboBun strain of Ebola
The Centers for Disease Control and Prevention (CDC) is a subsidiary of the pharmaceutical industry and holds more than 20 vaccine patents. The CDC does not sell vaccines but instead buys them at bulk discounts and offers them for free to children who cannot afford them.
The CDC holds a patent for the EboBun strain of the Ebola virus, which is different from the Ebola Zaire (EBOV) virus, the cause of the 2014 outbreak. The CDC was granted this patent in 2010, and it sparked much controversy, with numerous reports claiming that the U.S. Government was trying to profit from the deadly disease. The patent, known as Patent No. CA2741523A1, was filed for an isolated human Ebola virus denoted as Bundibugyo (EboBun) and deposited with the CDC in Atlanta, Georgia, on November 26, 2007.
The CDC's patent application states that the invention provides an isolated human Ebola virus that is genetically distinct, differing by more than 30% at the genome level from all other known ebolavirus species. This genetic distinction is significant as it allows for the design of diagnostic assays to monitor Ebola HF disease in humans and animals, as well as the development of effective antivirals and vaccines.
The CDC's rationale for pursuing the Ebola patent is to avoid paying costly licensing fees to private research and development companies. By holding the patent, the CDC can also make their information and studies publicly available, expediting the discovery of vaccines and cures. However, there is speculation about the government's motivation, with some believing it is driven by the potential for significant financial gains from patent licensing.
Vaccines: Can You Still Be Contagious After?
You may want to see also
Explore related products
The CDC also holds patents for other technologies, such as nasal drug delivery
The CDC does hold patents related to vaccines and vaccine technologies, but it does not sell vaccines. Instead, the CDC buys vaccines in bulk at discounted prices and distributes them for free to children from low-income families. The CDC also holds patents for other technologies, such as nasal drug delivery.
The CDC's Technology Transfer Office explains that researchers at the CDC may develop new technologies that could be of interest to companies. To "advance the CDC's public health mandate", these technologies are made available to the private sector through licenses. Companies can then use this technology to develop products such as vaccines. The CDC received $17 million in royalties from patented and unpatented technologies in 2019.
The CDC holds a patent for a method and apparatus for nasal drug delivery. This invention comprises a first tube in fluid communication with a means for generating negative pressure and a second tube in fluid communication with an aerosol. When the first tube is placed in one nostril and the second tube in the other, the negative pressure applied to the first tube creates a negative pressure within the nasal cavity, causing the aerosol to be drawn into the nasal passages and deposited on an internal nasal surface.
The CDC also holds patents related to the Zika virus, the influenza A virus, and the Ebola virus. These patents cover inventions such as recombinant antigens, improved purification methods for anthrax protective antigens, and live attenuated VDV1 (VERO-Derived Dengue serotype 1 virus) strains.
Vaccines in USA and Europe: What's the Difference?
You may want to see also
Frequently asked questions
Yes, the CDC holds patents on drugs such as a nasal drug delivery apparatus and an anthrax protective antigen.
Yes, the CDC holds patents on vaccines such as the Zika virus vaccine, the influenza A vaccine, and the Ebola vaccine.
The CDC holds vaccine patents to facilitate the development and transition of CDC innovations into products that benefit the health of Americans and people worldwide.
No, the CDC does not sell vaccines. Instead, they buy vaccines at a discount and distribute them for free, particularly to children who cannot afford them.
